Please login to the form below

Not currently logged in
Email:
Password:

EU approves Janssen's prostate cancer drug

The European Commission has approved Janssen-Cilag's Zytiga, a treatment for metastatic castration-resistant prostate cancer (mCRPC)

Janssen-Cilag has announced that the European Commission (EC) has approved its late stage prostate cancer drug Zytiga (abiraterone acetate) for marketing. The approval follows an accelerated regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).

Zytiga is a novel, once-daily, oral, androgen biosynthesis inhibitor, which when combined with prednisone or prednisolone, acts as a treatment for metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Professor Karim Fizazi, Department of Cancer Medicine, Institute Gustave Roussy, France, commented that Zytiga "gives new hope to men who are suffering from this late stage of prostate cancer" and that it helps them "live longer with a better quality of life and less pain."

8th September 2011

Share



Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Serviceplan Health & Life

We are your creative global lead agency, your Pan-European hub and your worldwide network....

Latest intelligence

The changing regulatory environment
Code of practice changes are encouraging transparency in pharma/HCP relationships...
Online Physician Communities
Study highlights value of internet for doctors in Eastern Europe
Electronic direct mail is proving popular as online access increases...
England’s clinical commissioning landscape
Who are the real masters in the new NHS?...